Human serum acylcarnitine profiles in different glucose tolerance states

Diabetes Research and Clinical Practice

Volumn 104, Issue 3, 2014, Pages 376-382

  Zhang, Xiuying ^a   Zhang, Chunfang ^a   Chen, Ling ^a   Han, Xueyao ^a   Ji, Linong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Carnitine; Mass spectrometry; Metabolism; Pre diabetes; Type 2 diabetes

Indexed keywords

3 HYDROXY HEXADECANOYLCARNITINE; ACYLCARNITINE; CARNITINE; GLUCOSE; PALMITOYLCARNITINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLUCOSE TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

CARNITINE; MASS SPECTROMETRY; METABOLISM; PRE-DIABETES; TYPE 2 DIABETES;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARNITINE; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PREDIABETIC STATE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84902540291     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.013     Document Type: Article

References (37)

1. Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
2. Booth G.L., Kapral M.K., Fung K., Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368:29-36.
3. Pignone M., Alberts M.J., Colwell J.A., Cushman M., Inzucchi S.E., Mukherjee D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010, 33:1395-1402.
4. Drosatos K., Schulze P.C. Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 2013, 10:109-121.
5. Bardini G., Rotella C.M., Giannini S. Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and beta-cell dysfunction on micro- and macrovascular complications. Rev Diabet Stud 2012, 9:82-93.
6. Kusminski C.M., Shetty S., Orci L., Unger R.H., Scherer P.E. Diabetes and apoptosis: lipotoxicity. Apoptosis 2009, 14:1484-1495.
7. Abdul-Ghani M.A., Muller F.L., Liu Y., Chavez A.O., Balas B., Zuo P., et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab 2008, 295:E678-E685.
8. Feller A.G., Rudman D. Role of carnitine in human nutrition. J Nutr 1988, 18:541-547.
9. DiPalma J.R., Carnitine deficiency. Am Fam Physician 1988, 38:243-251.
10. Pande S.V. Carnitine and intermediary metabolism. Union Med Can 1988, 117:116-119.
11. Ramsay R.R., Gandour R.D., van der Leij F.R. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 2001, 1546:21-43.
12. Bieber L.L., Carnitine Annu Rev Biochem 1988, 57:261-283.
13. Mingrone G. Carnitine in type 2 diabetes. Ann NY Acad Sci 2004, 1033:99-107.
14. Mynatt R.L. Carnitine and type 2 diabetes. Diabetes Metab Res Rev 2009, 25(Suppl. 1):S45-S49.
15. Vidal-Casariego A., Burgos-Peláez R., Martínez-Faedo C., Calvo-Gracia F., Valero-Zanuy MÁ, Luengo-Pérez L.M., et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes 2013, 121:234-238.
16. Keung W., Ussher J.R., Jaswal J.S., Raubenheimer M., Lam V.H., Wagg C.S., et al. Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice. Diabetes 2013, 62:711-720.
17. Ferrannini E., Buzzigoli G., Bevilacqua S., Boni C., Del Chiaro D., Oleggini M., et al. Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol 1988, 255:E946-E952.
18. Ringseis R., Keller J., Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr 2012, 51:1-18.
19. Stephens F.B., Constantin-Teodosiu D., Greenhaff P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007, 581:431-444.
20. Capaldo B., Napoli R., Di Bonito P., Albano G., Saccà L. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991, 14:191-195.
21. Wall B.T., Stephens F.B., Constantin-Teodosiu D., Marimuthu K., Macdonald I.A., Greenhaff P.L. Chronic oral ingestion of l-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J Physiol 2011, 589:963-973.
22. Power R.A., Hulver M.W., Zhang J.Y., Dubois J., Marchand R.M., Ilkayeva O., et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007, 50:824-832.
23. Poorabbas A., Fallah F., Bagdadchi J., Mahdavi R., Aliasgarzadeh A., Asadi Y., et al. Determination of free l-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 2007, 61:892-895.
24. Tamamoǧullari N., Siliǧ Y., Içaǧasioǧlu S., Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications 1999, 13:251-253.
25. Pregant P., Kaiser E., Schernthaner G. No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients. Clin Investig 1993, 71:610-612.
26. Ha C.Y., Kim J.Y., Paik J.K., Kim O.Y., Paik Y.H., Lee E.J., et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf) 2012, 76:674-682.
27. Adams S.H., Hoppel C.L., Lok K.H., Zhao L., Wong S.W., Minkler P.E., et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009, 139:1073-1081.
28. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998, 15:539-553.
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
30. McGarry J.D., Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997, 244:1-14.
31. Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G., et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity 2010, 18:1695-1700.
32. An J., Muoio D.M., Shiota M., Fujimoto Y., Cline G.W., Shulman G.I., et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med 2004, 10:268-274.
33. Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O., et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008, 7:45-56.
34. Hulver M.W., Berggren J.R., Cortright R.N., Dudek R.W., Thompson R.P., Pories W.J., et al. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 2003, 284:E741-E747.
35. Kelley D.E., Simoneau J.A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:2349-2356.
36. Möder M., Kiessling A., Löster H., Brüggemann L. The pattern of urinary acylcarnitines determined by electrospray mass spectrometry: a new tool in the diagnosis of diabetes mellitus. Anal Bioanal Chem 2003, 375:200-210.
37. Dellow W.J., Chambers S.T., Lever M., Lunt H., Robson R.A. Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diabetes Res Clin Pract 1999, 43:91-99.